Clinical Trial Search

Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 15.9; 28.0; 30.7 percentage of participants — p=0.0062

Primary: Percentage of Participants Who Achieved a Clinical State of Minimal Disease Activity (MDA-Joints) Response at Week 16 — 16.0; 33.9 percentage of participants — p=0.0008

Primary: Patient Function Response to Biologic Therapy as Measured by RAPID3 — -1.11 change in score

Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 19.0; 30.4; 38.1 percentage of participants — p=0.0001

Primary: Percentage of Participants Who Developed Psoriatic Arthritis (PsA) — 47.4; 35.7; 17.3; 10.3 Percentage of participants

Primary: American College of Rheumatology 20 (ACR20) Response at Week 12 — 24.3; 58.0; 51.9 percentage of participants — p=<0.001

Primary: Percentage of Participants With Psoriatic Arthritis (PsA) Based on Physical Examination, Medical History and Laboratory Results — 30.0 Percentage of participants

Primary: Proportion of Patients Achieving American College of Rheumatology 20 (ACR20) Response Criteria on Secukinumab Versus Placebo at Week 24 — 58; 67; 22 Participants

Primary: Change From Baseline in the Composite Score of BME, Synovitis, and Tenosynovitis Assessed by PsAMRIS at Week 24 — -2.32 score on a scale

Primary: Percentage of Participants With a Modified American College of Rheumatology 20% (ACR 20) Response at Week 12 — 35.8; 43.5; 11.8 percentage of participants — p=0.002

Primary: Proportion of ACR 20 Responders at Day 169 — 39.4; 22.3 Percentage of participants — p=<0.001

Primary: Percentage of Participants With Response to Treatment (300 mg AIN457) as Assessed by the ASAS20 Criteria at Week 12 — 66.3; 62.9; 31.2 percentage of participants…

Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 — 24.1; 56.9; 63.8 percentage of participants — p=<0.0001

Primary: Percent of Patients Achieving ACR20 Response Criteria on Secukinumab 75 or 150 mg vs. Placebo — 50.5; 50.0; 17.3 % participant — p=<0.0001

Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 — 36.2; 65.0; 70.6; 78.5 percentage of participants — p=<0.0001

Primary: Percentage of Participants Who Achieved Low Disease Activity (LDA) Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 6 — 43.1; 46.9; 33.4; 4.0…

Primary: Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 52 — 67.4; 61.5 Percentage of Participants — p=0.0719

Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 18.3; 28.4; 40.7 percentage of participants — p=<0.0001

Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 — 50.7; 60.9; 65.0 percentage of participants — p=0.005

Primary: Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20) — 29.3; 46.3; 52.4; 39.0 percentage of participants

Primary: Percent of Patients Achieving American College of Rheumatology Score of at Least 20% (ACR20) Response Criteria on Secukinumab 300 mg and 150 mg vs. Placebo at Week 16…

Primary: Number of Participants With American College of Rheumatology 20 (ACR20) Response — 47; 45; 21 Participants — p=0.0002

Primary: Work Productivity and Activity Impairment Psoriatic Arthritis Questionnaire (WPAI:PsA) Percentage of Overall Work Impairment (OWI): Change From Baseline to Week 24…

Primary: American College of Rheumatology (ACR) 20 Response at Week 14 — 10; 74; 66; 140 Participants — p=<0.001

Primary: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14 — 21.8; 75.1 Percentage of Participants — p=<0.001

Primary: Psoriatic Arthritis Disease Activity Score (PASDAS) at 24 Weeks — 3.09; 2.70 score on a scale — p=0.064

Primary: Percentage of Participants Who Achieved at Least an American College of Rheumatology 20 (ACR20) Response at Week 12 — 29.2; 35.2; 53.3; 54.2 percentage of participants…

Primary: Percentage of Participants Achieving American College of Rheumatology 20 Index (ACR20) — 19.5; 53.3; 48.0 Percentage of Participants — p=<0.001

Primary: Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 16 — 20.2; 38.2 percentage of participants — p=0.0040

Primary: Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Month 3 — 49.62; 46.97; 23.66 Percentage…